Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 12.
doi: 10.1002/mdc3.70355. Online ahead of print.

Is Dysphagia in Multiple System Atrophy Responsive to Levodopa? Results from a Retrospective Study

Florin Gandor  1   2   3   4 , Luise Berger  2   3 , Vera Jäger  2 , Katharina Demmin  2 , Doreen Gruber  2   3   5 , Katja Schimming  2 , Paulina Thimm  2 , Georg Ebersbach  2 , Stefanie Schreiber  3 , Dominic Rowe  1 , Annemarie Vogel  2
Affiliations

Is Dysphagia in Multiple System Atrophy Responsive to Levodopa? Results from a Retrospective Study

Florin Gandor et al. Mov Disord Clin Pract. .

Abstract

Background: Dysphagia remains a major clinical concern in multiple system atrophy (MSA), and so far, lacks relevant treatment options.

Objective: To systematically assess levodopa-responsiveness of dysphagia in MSA.

Methods: 19 MSA-patients underwent endoscopic swallowing evaluation in Off- and On-state, following an adapted FEES-levodopa-test-protocol. Findings were compared between states and correlated to disease-specific and demographic factors.

Results: All 19 MSA-patients 70 [66-72] years, 15/4 MSA-P/ C, 10 women exhibited dysphagia. Levodopa-responsiveness of motor-impairment was poor (UPDRS-3 Off 46 [34-52] vs On 43 [40-48], P = 0.31). Dysphagia severity varied greatly. Sum-scores ranged between 9-21 in Off and 6-20 in On. MSA-P-patients were more likely to have higher sum-scores (rpb 0.41, P = 0.01). Sum-scores otherwise were independent of disease-specific and demographic factors. 3/19 MSA-patients showed marked score-improvement by ≥30% through reduced leaking and aspiration but remained unchanged for the majority. Scores worsened in 2/19 patients. In the group analysis, the median dysphagia-score remained unchanged (2 [1, 2], P = 0.28). The occurrence of leaking, pharyngeal residue, penetration, and aspiration was not changed (P = 0.13-0.19). Severity of leaking was reduced (3 [2-4] vs. 0[0.5-1], P < 0.0001), while severity of pharyngeal residue, penetration, and aspiration remained unchanged (P = 0.29-0.53). Liquids were more often associated with leaking (P < 0.05) and aspiration (P < 0.005). All patients exhibited laryngeal movement disorders, with irregular arytenoid cartilage movements (iACM) being observed in all patients, regardless of levodopa-state.

Conclusion: The levodopa-response in MSA-related dysphagia varies greatly. Some patients might improve markedly, necessitating individual assessments to tailor patient-specific therapies. Non-pharmacological measures should be investigated to address dysphagia in MSA. IACM again proved to be highly prevalent in MSA.

Keywords: FEES; dysphagia; levodopa‐responsiveness; multiple system atrophy; treatment.

PubMed Disclaimer

References

    1. Fanciulli A, Wenning GK. Multiple‐system atrophy. N Engl J Med 2015;372:249–263. https://doi.org/10.1056/NEJMra1311488.
    1. Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord 2022;37:1131–1148. https://doi.org/10.1002/mds.29005.
    1. Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU. The differential diagnosis and treatment of atypical parkinsonism. Dtsch Arztebl Int 2016;113(5):61–69. https://doi.org/10.3238/arztebl.2016.0061.
    1. Müller J, Wenning GK, Verny M, et al. Progression of dysarthria and dysphagia in postmortem‐confirmed parkinsonian disorders. Arch Neurol 2001;58:259–264. https://doi.org/10.1001/archneur.58.2.259.
    1. Higo R, Nito T, Tayama N. Swallowing function in patients with multiple‐system atrophy with a clinical predominance of cerebellar symptoms (MSA‐C). Eur Arch Otorrinolaringol 2005;262:646–650. https://doi.org/10.1007/s00405-004-0883-0.

LinkOut - more resources